Cat.No. : CSC-RO0644 Host Cell: HEK293
| Cat. No. | CSC-RO0644 |
| Description | This cell line is engineered to stably overexpress SARS-CoV2 S Protein in HEK293 cells. |
| Gene | SARS-CoV2 S |
| Host Cell | HEK293 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Study the mechanisms of viral entry and replication 2. Research and in vitro screening of potential drugs 3. Vaccine development 4. The production of pseudotyped viruses |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Media Type | Cells were cultured in DMEM supplemented with 10% fetal bovine serum. |
| Growth Properties | Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2. Split at 80-90% confluence, approximately 1:3-1:6. |
| Freeze Medium | Complete medium supplemented with 10% (v/v) DMSO |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
SARS-CoV2's spike (S) protein infects host cells, making it a key therapy target. The researchers wanted to develop powerful single-domain antibodies (sdAbs) that targeted viral peptides in the S protein's cleavage site and receptor binding region. To interfere with proteolytic processing and lower viral infectivity, they chose and defined sdAbs against a peptide covering the polybasic cleavage site. Their findings showed that both the anti-cleavage site and receptor binding domain sdAbs effectively inhibited the infectivity of pseudoviruses expressing the CoV2 S protein. The researchers conducted extensive evaluations, including gel filtration chromatography and flow cytometry, to confirm the structural integrity and surface expression of the S protein in HEK293T cells.
Figure 1. The researchers employed HEK293T cells, producing LV(CoV2-S) and LV(BALD), to investigate the inhibitory effects of anti-CSP and anti-RBD sdAbs on cell-to-cell fusion. (Singh S, et al., 2022)
Creative Biogene's Human SARS-CoV2 S Protein Stable Cell Line - HEK293 provides a robust platform for functional assays, enabling precise investigations into the interactions between sdAbs and the S protein. Researchers can utilize this stable cell line to explore various aspects of SARS-CoV2 biology and test new therapeutic agents, ultimately contributing to our understanding and management of COVID-19.
A: The SARS-CoV2 S gene encodes for the spike protein, which is a key component of the virus's envelope. The spike protein allows the virus to bind to ACE2 receptors on human cells, facilitating entry into the host cell and initiating infection.
A: The SARS-CoV2 S gene enables viral transmission by producing the spike protein, which mediates the attachment and fusion of the virus with host cell membranes. This interaction is critical for the virus to cross cellular barriers and spread throughout the body.
A: Yes, several SARS-CoV2 variants have mutations in the S gene, some of which can affect the virus's transmissibility, antigenicity, and potentially the severity of the disease it causes. These mutations can alter the spike protein's conformation and its interaction with ACE2 receptors or antibodies.
A: Many COVID-19 vaccines and therapeutic antibodies target the SARS-CoV2 S gene and its spike protein. By inducing an immune response against the spike protein, these vaccines aim to prevent viral entry into cells, while therapeutics can neutralize the virus or block its interaction with ACE2 receptors.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The SARS-CoV2 S Protein Stable Cell Line - HEK293 exhibits robust growth and maintains a stable morphology similar to wild-type HEK293 cells. This similarity is beneficial for comparative studies, ensuring minimal impact of confounding factors and facilitating accurate interpretation of experimental results.
This cell line serves as a valuable tool for functional studies, enabling researchers to investigate the role of the SARS-CoV2 S protein in viral entry, fusion, and pathogenesis. Its utility in understanding the mechanisms of SARS-CoV2 infection makes it an essential resource for advancing our knowledge of COVID-19 and developing effective countermeasures.
The provider of the SARS-CoV2 S Protein Stable Cell Line - HEK293 delivers thorough technical assistance and extensive documentation, equipping investigators with the essential tools and direction for the efficient application of the cell line in their experiments.
The SARS-CoV2 S Protein Stable Cell Line - HEK293 is produced and utilized in strict compliance with safety and ethical guidelines. This ensures responsible research practices and reduces potential risks related to the use of genetically modified cell lines. Such adherence to standards reassures the ethical practice of scientific research and safeguards both researchers and the general public from unforeseen negative outcomes.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
